skip navigation

Skip Nav

Ensayos clínicos

Ensayos clínicos

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected with HIV

Patrocinador(es) del estudio: National Institute of Allergy and Infectious Diseases (NIAID)
Números de identificación: NCT00000940, ACTG 371
  • Concluido

Propósito del estudio

This study will determine what effect taking a combination of five anti-HIV drugs during the early stage of HIV infection, then temporarily stopping them once or twice, may have on the amount of HIV virus in the blood (viral load). The study will also evaluate the safety and effectiveness of this anti-HIV drug combination.

Afección:Fase:
Infecciones por el VIH
Fase 2

Detalles del estudio

Acute, primary HIV infection represents a potentially unique opportunity to eradicate the infection. Although plasma viral load rises rapidly, the dominant infecting virus is relatively uniform genetically, and infection may not be fully established in all tissue sites until some time after exposure. Current antiretroviral therapy is able to reduce plasma viral load to unmeasurable levels in established infection. However, there are many questions that remain about the treatment of primary HIV infection. While it is assumed that aggressive antiretroviral regimens are required, it is not known how long they must be continued. It is hoped that after an interval of aggressive therapy, the number of agents could be safely reduced. This study evaluates if viral suppression can be sustained after study therapy is withdrawn.



Participants in this study will receive lamivudine (3TC), stavudine (d4T), abacavir (ABC), amprenavir (APV), and ritonavir (RTV) for at least 52 weeks. During this induction phase, participants will be followed through regular study visits every 4 or 8 weeks. If the participant’s viral load and CD4 counts are within study parameters at the end of 52 weeks, the participant will discontinue all antiretroviral medications simultaneously. Participants in the treatment interruption phase will be followed weekly initially, every 2 weeks for 8 weeks, and then every 4 or 8 weeks. Treatment may be restarted if necessary during this phase based on viral load and CD4 counts. If treatment is restarted, the participant will receive 3TC, d4T, APV, and RTV but not ABC. During this reinduction phase, participants will be followed every 4 or 8 weeks.



Depending on viral load and CD4 counts, participants may be eligible for a second treatment interruption phase following the reinduction phase. Participants will once again stop all antiretroviral medications simultaneously and will have the same monitoring as in the first treatment interruption phase. Following this second treatment interruption, participants will be restarted on 3TC, d4T, APV, and RTV and will be evaluated at Weeks 4, 8, 16, and 24, at which time participants go off study.



The length of study participation for individual participants will vary. The length of each phase will be highly dependent on the participant’s laboratory parameters. In general, participants will be enrolled in the study for 3 to 4 years. Participants may also enroll in immunology, compartment, pharmacology, and medication compliance substudies.Acute, primary HIV infection represents a potentially unique opportunity to eradicate the infection. Although plasma viral load rises rapidly, the dominant infecting virus is relatively uniform genetically, and infection may not be fully established in all tissue sites until some time after exposure. Current antiretroviral therapy is able to reduce plasma viral load to unmeasurable levels in established infection. However, there are many questions that remain about the treatment of primary HIV infection. While it is assumed that aggressive antiretroviral regimens are required, it is not known how long they must be continued. It is hoped that after an interval of aggressive therapy, the number of agents could be safely reduced. This study evaluates if viral suppression can be sustained after study therapy is withdrawn.



Participants in this study will receive lamivudine (3TC), stavudine (d4T), abacavir (ABC), amprenavir (APV), and ritonavir (RTV) for at least 52 weeks. During this induction phase, participants will be followed through regular study visits every 4 or 8 weeks. If the participant’s viral load and CD4 counts are within study parameters at the end of 52 weeks, the participant will discontinue all antiretroviral medications simultaneously. Participants in the treatment interruption phase will be followed weekly initially, every 2 weeks for 8 weeks, and then every 4 or 8 weeks. Treatment may be restarted if necessary during this phase based on viral load and CD4 counts. If treatment is restarted, the participant will receive 3TC, d4T, APV, and RTV but not ABC. During this reinduction phase, participants will be followed every 4 or 8 weeks.



Depending on viral load and CD4 counts, participants may be eligible for a second treatment interruption phase following the reinduction phase. Participants will once again stop all antiretroviral medications simultaneously and will have the same monitoring as in the first treatment interruption phase. Following this second treatment interruption, participants will be restarted on 3TC, d4T, APV, and RTV and will be evaluated at Weeks 4, 8, 16, and 24, at which time participants go off study.



The length of study participation for individual participants will vary. The length of each phase will be highly dependent on the participant’s laboratory parameters. In general, participants will be enrolled in the study for 3 to 4 years. Participants may also enroll in immunology, compartment, pharmacology, and medication compliance substudies.

Criterios de inclusión

    • Acute HIV infection (recently infected with HIV or recent seroconversion)
    • Karnofsky status of 80 or greater within 14 days prior to study entry
    • Acceptable methods of contraception
    • Able and willing to give written informed consent

Criterios de exclusión

    :
    • Previously received anti-HIV drugs
    • Hepatitis within 30 days prior to study entry
    • Pancreatitis within 120 days prior to study entry
    • Radiation or chemotherapy within 30 days prior to study entry
    • Certain medications within 14 days prior to study entry
    • Experimental or investigational therapy within 30 days prior to study entry
    • Illness (non-HIV infection, cancer, etc.) at the time of study entry
    • Pregnant or breastfeeding

Centros de estudio/contactos

California

    UCLA CARE Center CRS, Los Angeles, California, 90035, United States

    USC CRS, Los Angeles, California, 90033, United States

    Ucsd, Avrc Crs, San Diego, California, 92103, United States

    Ucsf Aids Crs, San Francisco, California, 94110, United States

Colorado

    University of Colorado Hospital CRS, Aurora, Colorado, 80045, United States

Hawaii

    Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, 96816, United States

Massachusetts

    Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, 02114, United States

    SSTAR, Family Healthcare Ctr., Fall River, Massachusetts, 02720, United States

Missouri

    Washington U CRS, St. Louis, Missouri, 63110, United States

New York

    NY Univ. HIV/AIDS CRS, New York, New York, 10016, United States

    Beth Israel Med. Ctr. ACTU, New York, New York, 10003, United States

    HIV Prevention & Treatment CRS, New York, New York, 10032, United States

    Univ. of Rochester ACTG CRS, Rochester, New York, 14642, United States

    AIDS Care CRS, Rochester, New York, 14607, United States

    McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit, Rochester, New York, 14642, United States

North Carolina

    Unc Aids Crs, Chapel Hill, North Carolina, 27514, United States

Pennsylvania

    Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, 19104, United States

Rhode Island

    The Miriam Hosp. ACTG CRS, Providence, Rhode Island, 02906, United States

Actualizado: 13 de octubre del 2004

Volver arriba